Related Experiment Video
Updated: Aug 7, 2025

Assays for the Degradation of Misfolded Proteins in Cells
Published on: August 28, 2016
The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
Ellis G Jaffray1, Michael H Tatham1, Barbara Mojsa1
1Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee , Dundee, UK.
Abstract:
Acute Promyelocytic Leukemia is caused by expression of the oncogenic Promyelocytic Leukemia (PML)-Retinoic Acid Receptor Alpha (RARA) fusion protein. Therapy with arsenic trioxide results in degradation of PML-RARA and PML and cures the disease. Modification of PML and PML-RARA with SUMO and ubiquitin precedes ubiquitin-mediated proteolysis. To identify additional components of this pathway, we performed proteomics on PML bodies. This revealed that association of p97/VCP segregase with PML bodies is increased after arsenic treatment. Pharmacological inhibition of p97 altered the number, morphology, and size of PML bodies, accumulated SUMO and ubiquitin modified PML and blocked arsenic-induced degradation of PML-RARA and PML. p97 localized to PML bodies in response to arsenic, and siRNA-mediated depletion showed that p97 cofactors UFD1 and NPLOC4 were critical for PML degradation. Thus, the UFD1-NPLOC4-p97 segregase complex is required to extract poly-ubiquitinated, poly-SUMOylated PML from PML bodies, prior to degradation by the proteasome.
Insights
Arsenic therapy for acute promyelocytic leukemia degrades the toxic PML-RARA protein. The p97 enzyme complex is crucial for this degradation process by extracting modified PML proteins from PML bodies.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Acute Promyelocytic Leukemia (APL) is driven by the oncogenic Promyelocytic Leukemia (PML)-Retinoic Acid Receptor Alpha (RARA) fusion protein.
- Arsenic trioxide therapy effectively treats APL by inducing degradation of PML-RARA and PML proteins.
- SUMOylation and ubiquitination of PML and PML-RARA precede their proteasomal degradation.
Purpose of the Study:
- To identify novel protein components involved in the arsenic-induced degradation pathway of PML and PML-RARA.
- To elucidate the role of the p97/VCP segregase complex in the processing of PML bodies.
Main Methods:
- Proteomics analysis of PML bodies.
- Pharmacological inhibition and siRNA-mediated depletion of p97/VCP.
- Immunofluorescence microscopy to visualize PML bodies and protein localization.
- Western blotting to assess protein modification and degradation.
Main Results:
- Proteomics identified increased association of p97/VCP segregase with PML bodies upon arsenic treatment.
- Inhibition of p97 disrupted PML body morphology, increased SUMO- and ubiquitin-modified PML, and blocked arsenic-induced degradation.
- p97 cofactors UFD1 and NPLOC4 were essential for PML degradation.
- The UFD1-NPLOC4-p97 complex extracts modified PML from PML bodies for proteasomal degradation.
Conclusions:
- The UFD1-NPLOC4-p97 segregase complex plays a critical role in arsenic-induced degradation of PML and PML-RARA in APL.
- This complex facilitates the extraction of ubiquitinated and SUMOylated PML from PML bodies, enabling proteasomal degradation.
- Targeting the p97 pathway may offer new therapeutic strategies for APL.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
Negative Regulator Molecules
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Nuclear Export of mRNA
Anaphase Promoting Complex

